Gene Therapy for Parkinson's Disease, An Update

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Current Parkinson's disease (PD) treatment, dopamine replacement therapy, has side effects and does not halt disease progression.
• Gene therapy presents a promising avenue for advancing PD treatment strategies.

Purpose of the Study:

• To review the current status of gene therapy applications for Parkinson's disease.
• To evaluate both symptomatic and disease-modifying gene therapy approaches.

Main Methods:

• Review of preclinical and clinical studies involving gene therapy for PD.
• Analysis of transgenes targeting dopamine/GABA synthesis and neurotrophic factors.
• Exploration of optogenetics, chemogenetics, and genome editing for PD.

Main Results:

• Non-disease modifying gene therapies targeting neurotransmitter synthesis show promise for symptom improvement in clinical studies.
• Disease-modifying therapies using neurotrophic factors (e.g., neurturin, GDNF) have shown preclinical efficacy but failed to meet primary endpoints in clinical trials.
• Novel approaches like opto- and chemogenetics, and genome editing are emerging for PD treatment.

Conclusions:

• Gene therapy holds significant potential for both symptomatic relief and disease modification in Parkinson's disease.
• Further clinical trials, particularly with neurotrophic factors, are warranted to explore disease-slowing possibilities.
• Emerging technologies offer future personalized gene therapy options for PD.